Forxiga approved in Japan for chronic heart failure
30 November 2020 07:00 GMT Forxiga approved in Japan for chronic heart failure Forxiga is the first SGLT2 inhibitor approved in Japan for chronic heart failurewith reduced ejection fraction in adult patients with and without type-2 diabetes AstraZeneca's Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving standard of care. HF is a life-threatening chronic disease that prevents the heart from pumping sufficient levels of blood around the body. It affects approximately 64 million people worldwide, at